Four years after he resigned as chief medical officer at Novartis in the wake of a restructuring at the Big Pharma, John Tsai ...

Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief ...

BostonGene and Daiichi Sankyo are collaborating to integrate AI-driven translational intelligence into an antibody-drug ...

Daiichi Sankyo has named John Tsai as its new chief medical officer (CMO), replacing Ken Takeshita, who is stepping down after five years in the role on 1st April.

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). The collaboration will integrate ...

Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effective April 1, 2026.

Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. Despite the success of Enhertu, the company has experienced two latest hiccups: the discontinuation of internal ...

If you are wondering whether Daiichi Sankyo Company is starting to look like a bargain or still has room to fall, you are not alone; this stock has quietly shifted from market favorite to value ...

In a win for Daiichi Sankyo’s big pivot to oncology, the Japanese drugmaker has snatched its first U.S. cancer nod since 2011—and it’s also the first FDA-approved drug for a rare joint tumor. The FDA ...

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca's ...

Following its demutualization and IPO in 2010, Daiichi Life Group has transformed from one of Japan’s big four traditional life insurers to a multinational holding company with a multibrand, ...

After a string of new approvals, Daiichi Sankyo is boosting sales projection for AstraZeneca-partnered star cancer drug Enhertu. Daiichi now expects Enhertu could reach sales of 195.2 billion Japanese ...